Companies in the drug, biologic and medical device spaces may encounter compliance challenges, some of which can lead to government enforcement actions and potential civil, and even criminal, liability. With a constantly evolving regulatory landscape to navigate, how can you address risks while achieving your business objectives? Join Foley Hoag for a multi-part webinar series exploring crisis scenarios facing FDA-regulated companies, with roundtable discussions on actions your company can take to navigate these challenging issues.
Part II: Addressing Whistleblower Complaints in an FDA Regulated Company
While most companies encourage employees to report internal concerns, many are unprepared to respond when a whistleblower complaint arises. How can companies prioritize actions and responses when whistleblowers allege misconduct that could cause reputational harm? We discussed the key strategies your company can take to better prepare for and handle an investigation triggered by whistleblowers.
Panelists
- Bryant Godfrey, Partner, Co-Chair, FDA Practice, Foley Hoag LLP
- Areta Kupchyk, Partner, Co-Chair, Administrative Law Department and FDA Practice, Foley Hoag LLP
- Lynn Neils, Partner, Foley Hoag LLP
- Allison Anderson, Partner, Co-Chair, Labor & Employment Practice, Foley Hoag LLP
- Peter Sullivan, Partner, Foley Hoag LLP
